Reza Dana is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 592 publications with 31,646 citations (h-index 77); ClinicalTrials.gov lists 11 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 1% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Boston, MA 021143002
Telephone
617-573-4330Registry record last updated 5 Jun 2013.
Clinical trials
- Mucinex® for Treatment of Filamentary Keratitis
Sponsor: Massachusetts Eye and Ear Infirmary
- Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
Sponsor: Massachusetts Eye and Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dompe US, Inc.Program year20251 payment
- Amgen Inc.Program year20244 payments
- Glaukos CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
39.2%Macrolide21.9%Erythromycin100%Part D≥36 patientsTetracycline-class Drug12.6%Doxycycline Monohydrate100%Part D≥29 patients+ 1 more class in this area
Cancer & immunology
38.3%Calcineurin inhibitor38.3%Restasis55%Cyclosporine45%Part D≥39 patientsSensory organs
22.5%Corticosteroid11.6%Fluorometholone73%Prednisolone Acetate27%Part D<11 patientsRecombinant Human Nerve Growth Factor4.2%Oxervate100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
11 NIH research awards on record, funded 1995–2026 per NIH RePORTER. The latest:
- Mass Eye and Ear-Vision Clinical Scientist Development Program
Massachusetts Eye and Ear Infirmary
FY2026$603,501K12EY016335 - Immunopathogenic Mechanisms of Dry Eye Disease
Schepens Eye Research Institute
FY2026$587,562R01EY020889 - The Impact of Donor Diabetes on Corneal Immune Cells and Graft Survival
Schepens Eye Research Institute
FY2026$492,500R01EY033288
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Dean Eliott, MD
Massachusetts Eye and Ear Infirmary
Leo Kim, MD
Massachusetts Eye and Ear Infirmary
Daniel Liebman, MD
Massachusetts Eye and Ear Infirmary
Neil Bhattacharyya, MD, FACS
Massachusetts Eye and Ear Infirmary
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”